Sophie A. Blackburn
Fulvestrant for the treatment of advanced breast cancer
Blackburn, Sophie A.; Parks, Ruth M.; Cheung, Kwok-Leung
Ruth M. Parks
Professor KWOK_LEUNG CHEUNG Kwok_leung.Cheung@nottingham.ac.uk
Deputy Head of Education & Director of The Bmbs Medicine Programmes
Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy.
Areas covered: This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment.
Expert commentary: Within phase III trials, fulvestrant has demonstrated equivalent or improved clinical efficacy when compared with established endocrine agents. In the recent decade, fulvestrant has achieved licensing as a second line agent in non-operative advanced breast cancer at initially 250mg, increasing to 500mg. Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survival when compared to fulvestrant alone.
Blackburn, S. A., Parks, R. M., & Cheung, K. (2018). Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 18(7), 619-628. https://doi.org/10.1080/14737140.2018.1473038
|Journal Article Type||Article|
|Acceptance Date||May 2, 2018|
|Online Publication Date||May 11, 2018|
|Publication Date||May 15, 2018|
|Deposit Date||Jun 28, 2018|
|Publicly Available Date||May 12, 2019|
|Journal||Expert Review of Anticancer Therapy|
|Publisher||Taylor and Francis|
|Peer Reviewed||Peer Reviewed|
|Keywords||Fulvestrant, advanced breast cancer, endocrine therapy, pure anti-oestrogen|
|Additional Information||This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Anticancer Therapy on 11 May 2018, available online: http://www.tandfonline.com/10.1080/14737140.2018.1473038|
Fulvestrant- final edit.pdf